Supplements · Metabolic & Cardiometabolic
quercetin decreases blood pressure
In plain terms: Does quercetin lower your blood pressure?
Leans support Supplements 🔬 Includes disconfirming
Part of: 🧪 quercetin
RefutedContestedStrong support
consensus score 0.49
A little, if yours is already high and you take enough. Pooled trials show about 3 points systolic, but only at 500 mg a day or more, and healthy people with normal blood pressure got no benefit at any dose tested.
📅 Last reviewed: 2026-07-26 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
9 support 4 contradict 0 tested null 4 mixed · 17 sources, 13 independent groups
What the evidence shows
Real, small, and conditional on dose and on who you are. Two rigorous human meta-analyses (587 and 896 participants) agree on roughly -3 mmHg systolic and -2.6 to -2.9 mmHg diastolic. Crucially, one reports a DOSE THRESHOLD: significant only at 500 mg/day or above, null below it.
The evidence (18)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Huang H, Liao D, Dong Y, Pu R 2020 · Nutrition reviews | meta-analysis | supports | high | Meta-analysis of 17 RCTs (n=896) found quercetin lowered SBP by -3.09 mmHg (95% CI -4.59,-1.59; P=0.0001) and DBP by -2.86 mmHg (95% CI -5.09,-0.63; P=0.01). Lipid changes (HDL, TG) were significant only in parallel-design trials with >=8 w |
| Edwards RL, Lyon T, Litwin SE, Rabovsky A, Symons JD, Jalili T 2007 · The Journal of nutrition | RCT | mixed | moderate | Randomized crossover trial of 730 mg/d quercetin for 28 days found no BP change in prehypertensive subjects (n=19) but significant reductions in stage-1 hypertensive subjects (n=22): SBP -7, DBP -5, MAP -5 mmHg (all P<0.01), with no change |
| Zielińska D, Starowicz M, Wronkowska M, Zieliński H 2025 · Molecules (Basel, Switzerland) | in-vitro | supports | low | In vitro biochemical assay found quercetin was the most potent ACE inhibitor among rutin/quercetin-glucoside derivatives tested (ranking Q > Q3,4'G > Ru > Q3G > Q4'G), with ACE-inhibitory activity correlating with antioxidant potential (r= |
| Mkhize SA, Nthlane RA, Xhakaza SP, Verhaert PD, Baijnath S, Millen AME, Michel FS 2025 · Basic & clinical pharmacology & toxicology | animal | supports | low | In L-NAME-induced hypertensive female rats, acute intravenous quercetin (4.5 mg/kg) decreased BP and improved aortic pulse-wave velocity and renal/mesenteric vascular reactivity versus the L-NAME-only state; acute IV dosing in rats, not ora |
| Egert S, Bosy-Westphal A, Seiberl J, Kürbitz C, Settler U, Plachta-Danielzik S, Wagner AE, Frank J, Schrezenmeir J, Rimbach G, Wolffram S, Müller MJ 2009 · The British journal of nutrition | RCT | supports | moderate | Same 6-week crossover RCT (150 mg/d quercetin, n=93 overweight/obese with metabolic-syndrome traits) found SBP fell 2.6 mmHg in the entire group (P<0.01), 2.9 mmHg in the hypertensive subgroup, and 3.7 mmHg in younger adults (25-50y); no si |
| Tamtaji OR, Milajerdi A, Dadgostar E, Kolahdooz F, Chamani M, Amirani E, Mirzaei H, Asemi Z 2019 · Current pharmaceutical design | meta-analysis | mixed | moderate | Meta-analysis of 8 RCTs in metabolic-syndrome/related-disorder patients found a significant SBP reduction (WMD -1.69 mmHg; 95% CI -3.22,-0.17) but no significant DBP change (WMD -3.14 mmHg; 95% CI -8.24,1.95), and no significant effect on V |
| Silva-Cunha M, Conde-Tella SO, Rebelo MA, Kemmer ILM, Lima-Silva AK, Caetano ESP, Tanus-Santos JE 2026 · Basic & clinical pharmacology & toxicology | animal | mixed | low | In spontaneously hypertensive rats, oral quercetin (10 mg/kg) alone did not independently lower blood pressure, but it converted a subthreshold, non-antihypertensive nitrite dose (1 mg/kg) into an effective antihypertensive treatment via en |
| Popiolek-Kalisz J, Fornal E 2022 · Current problems in cardiology | meta-analysis | supports | high | Meta-analysis of 10 RCTs (n=841) found quercetin significantly lowered SBP overall (MD -2.38 mmHg, 95% CI -3.80 to -0.96, P=0.01) and in normotensives (MD -1.82 mmHg), and lowered DBP only in the (pre)hypertensive subgroup (MD -3.14 mmHg, 9 |
| Bondonno NP, Bondonno CP, Rich L, Mas E, Shinde S, Ward NC, Hodgson JM, Croft KD 2016 · The American journal of clinical nutrition | RCT | contradicts | moderate | Randomized crossover trial in 15 healthy volunteers given single acute doses of 50-400 mg quercetin-3-O-glucoside found no significant change in BP or endothelial function at any dose 60 min post-dose, despite dose-dependent increases in pl |
| Sivasubramanian MK, Monteiro R, Butcher JT, Venugopal U, Kesavan Y, Balasubramanian P, Subramanian M 2026 · GeroScience | animal | contradicts | low | In high-fat-diet obese mice, combined senolytic dasatinib+quercetin (5+50 mg/kg) improved cardiac autonomic balance (heart-rate variability) versus HFD controls but did not alter radiotelemetry-measured blood pressure or global sympathetic |
| Arabi SM, Shahraki Jazinaki M, Chambari M, Bahrami LS, Maleki M, Sukhorukov VN, Sahebkar A 2023 · Phytother Res | meta-analysis | mixed | moderate | Umbrella review of meta-analyses: 'As part of the umbrella review, we summarized pooled estimates, 95% CIs, heterogeneity, and publication bias.' SBP 'WMD: -1.9, 95% CI = -3.2 to -0.6, I2 = 88.3%'; DBP not affected. Units are syntheses (5 MAs of 18 RCTs, plus 5 newer RCTs); review — zero weight. |
| Serban MC, Sahebkar A, Zanchetti A, Mikhailidis DP, Howard G, Antal D, Andrica F, Ahmed A, Aronow WS, Muntner P, Lip GY, Graham I, Wong N, Rysz J, Banach M, Lipid and Blood Pressure Meta‐analysis Collaboration (LBPMC) Group 2016 · Journal of the American Heart Association | meta-analysis | supports | high | Meta-analysis of 7 RCTs/9 arms (n=587) found quercetin significantly reduced SBP (WMD -3.04 mmHg, P=0.028) and DBP (WMD -2.63 mmHg, P<0.001) overall. Dose-stratified analysis: effect significant at doses >=500 mg/d (SBP -4.45, DBP -2.98 mmH |
| Chopyak VV, Hayduchok IG, Fedorov YV, Kovpak AV, Baida BF, Levytska OV, Doroshko VA 2025 · Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti | observational | supports | low | Comparative study of 120 stage-II hypertension patients (randomization not stated) found quercetin (Corvitin) added to Ramipril/Amlodipine gave 'more pronounced' improvement in 24-hour BP-monitoring indices and dipper profile than standard |
| Mori A, Sakurai A, Takimoto S, Sakamoto K, Nakahara T 2026 · International journal of molecular sciences | animal | contradicts | moderate | In rats, intravenous quercetin (10-100 ug/kg/min) dose-dependently dilated retinal arterioles via a nitric-oxide mechanism, but systemic IV infusion caused no significant change in systemic blood pressure or heart rate. |
| Sagi SSK, Kirar V, Prasad J, Singh S, Rathi V, Sultana K, Singh VK, Verma SK, Kumar D, Kumar V, Saxena S, Mishra R, Singh VV, Chopra S, Varshney R 2026 · European journal of nutrition | RCT | supports | moderate | Double-blind RCT in 110 healthy lowlanders given 500 mg/day quercetin (bar) vs placebo for 15 days during high-altitude ascent found both SBP (-8 mmHg) and DBP (-4 mmHg) significantly lower in the quercetin group (p<0.001), alongside reduce |
| Mantadaki AE, Linardakis M, Vafeiadi M, Anastasiou F, Tsatsakis A, Symvoulakis EK 2024 · Cureus | RCT | contradicts | low | Interim analysis (38 of 100 enrolled) of an RCT in T2DM patients given 500 mg/d quercetin for 12 weeks found a numerically greater SBP drop than control (-7.4% vs -3.7%) that did not reach significance (P=0.117); the trial's significant fin |
| Egert S, Boesch-Saadatmandi C, Wolffram S, Rimbach G, Müller MJ 2010 · The Journal of nutrition | RCT | mixed | moderate | In a 6-week crossover RCT (150 mg/d quercetin) in 93 overweight/obese adults with metabolic-syndrome traits stratified by apoE genotype, SBP fell 3.4 mmHg (P<0.01) in apoE3 carriers (n=60) but showed no significant BP effect in apoE4 carrie |
| Mantadaki AE, Linardakis M, Tsakiri M, Baliou S, Fragkiadaki P, Vakonaki E, Tzatzarakis MN, Tsatsakis A, Symvoulakis EK 2024 · Journal of clinical medicine | RCT | supports | moderate | Open-label RCT in 88 completing T2DM patients given 500 mg/day quercetin for 12 weeks (with an 8-week washout then a repeat 12-week course) found SBP fell -5.0% vs -0.2% in controls (p=0.029), alongside improved HbA1c, FEV1, sleep and anxie |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.